MediWound Ltd., a biotech company specializing in enzymatic therapies for tissue repair, will announce its financial results for Q1 2026 on May 27. The company will hold a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. MediWound markets its FDA-approved product NexoBrid® for burn treatment and is developing EscharEx®, a therapy for chronic wound care. Investors can access the webcast live or replay it later on the company's website.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
SpaceX shares fell below their IPO price of $135 for the first time, dropping to $132.28 before closing slightly above at $135.27. The stock is down about 16% from its June 12 closing price and 36% from its peak on June 16. The decline reflects inves...
Latham Group is rated a Buy as it implements a new CEO-led strategy focusing on expanding its core market, increasing presence in the southern U.S., adopting automatic pool covers, and pursuing mergers and acquisitions. Despite challenges in the depr...
NYDIG projects Bitcoin might fall to $38,000-$39,000 by October 2026 if the current 2025-26 market decline matches the depth of the 2022 bear market. Bitcoin is currently trading near $64,500, down about 30% this year and roughly 50% below its Octobe...
PepsiCo is rated a strong buy due to its attractive combination of dividend yield, earnings growth, and undervaluation. The company is projected to achieve a forward compound annual growth rate (CAGR) between 13.7% and 18.2%, supported by dividend in...
